Bausch + Lomb (BLCO) Expected to Release Quarterly Earnings on Wednesday

Bausch + Lomb (NYSE:BLCO) is expected to be posting its Q3 2026 results before the market opens on Wednesday, October 28th. Analysts expect Bausch + Lomb to post earnings of $0.2145 per share and revenue of $1.37 billion for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 8:00 AM ET.

Bausch + Lomb (NYSE:BLCO) last issued its quarterly earnings data on Wednesday, July 29th. The company reported $0.15 EPS for the quarter, missing the consensus estimate of $0.16 by ($0.01). Bausch + Lomb had a positive return on equity of 4.14% and a negative net margin of 3.21%. The company had revenue of $1.39 billion during the quarter, compared to the consensus estimate of $1.37 billion. During the same quarter last year, the company posted ($0.18) earnings per share. The firm’s revenue for the quarter was up 9.1% compared to the same quarter last year. On average, analysts expect Bausch + Lomb to post $0.81 EPS for the current fiscal year and $1.04 EPS for the next fiscal year.

Bausch + Lomb Trading Down 0.2%

NYSE:BLCO opened at $17.44 on Monday. The company has a 50-day moving average price of $17.17 and a 200-day moving average price of $16.48. The stock has a market cap of $6.23 billion, a price-to-earnings ratio of -36.33, a P/E/G ratio of 0.55 and a beta of 0.56. The company has a current ratio of 1.55, a quick ratio of 1.02 and a debt-to-equity ratio of 0.79. Bausch + Lomb has a 12 month low of $14.44 and a 12 month high of $18.92.

Insider Transactions at Bausch + Lomb

In related news, Director Eschenbach Andrew C. Von sold 12,500 shares of the business’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $16.50, for a total transaction of $206,250.00. Following the sale, the director owned 69,792 shares of the company’s stock, valued at $1,151,568. The trade was a 15.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Frederick Munsch sold 52,900 shares of the company’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $16.78, for a total transaction of $887,662.00. Following the completion of the sale, the chief accounting officer owned 45,831 shares in the company, valued at approximately $769,044.18. This trade represents a 53.58% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 71,459 shares of company stock valued at $1,194,370. 1.45% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. Citigroup increased their price target on shares of Bausch + Lomb from $19.00 to $21.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. Evercore set a $17.00 price objective on shares of Bausch + Lomb in a report on Monday, July 6th. Barclays raised Bausch + Lomb to a “strong-buy” rating in a research report on Wednesday, October 7th. Leerink Partners assumed coverage on Bausch + Lomb in a report on Wednesday, September 9th. They set an “outperform” rating and a $24.00 target price on the stock. Finally, Weiss Ratings raised Bausch + Lomb from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 21st. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $19.46.

About Bausch + Lomb

Bausch + Lomb Corporation (NYSE: BLCO) is a global eye-health company that develops, manufactures and markets products for vision care, ophthalmic pharmaceuticals and eye surgery. The company serves consumers, eye-care professionals, hospitals and surgical centers through a portfolio spanning contact lenses, contact-lens care products, prescription medicines, over-the-counter eye-care products and surgical equipment.

Its vision-care portfolio includes the Biotrue and INFUSE contact-lens brands, as well as solutions and other products used to clean and maintain contact lenses.